Qelbree received FDA approval for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 [1][2]. The approval was granted in December 2021 [2]. Qelbree is a non-stimulant medication used to treat ADHD [1][3].
How does Qelbree work for ADHD?
Qelbree is a selective norepinephrine reuptake inhibitor (SNRI) [1][3]. It works by increasing the levels of norepinephrine, a neurotransmitter, in the brain [3]. Norepinephrine plays a role in regulating attention and impulsivity, which are often affected in individuals with ADHD [3]. Unlike stimulant medications, Qelbree does not have a direct effect on dopamine levels [3].
What is the active ingredient in Qelbree?
The active ingredient in Qelbree is viloxazine [1][2].
When did Qelbree become available?
Following its FDA approval in December 2021, Qelbree became available for prescription in the United States [2].
Who manufactures Qelbree?
Qelbree is manufactured by Supernus Pharmaceuticals [1][2].
What are the differences between Qelbree and stimulant ADHD medications?
Qelbree is a non-stimulant, whereas many common ADHD medications are stimulants, such as Adderall or Ritalin [3]. Stimulant medications work by increasing both norepinephrine and dopamine levels in the brain. Non-stimulants like Qelbree work more selectively on norepinephrine [3]. This difference means Qelbree may be an option for individuals who do not tolerate stimulants well or for whom stimulants have not been effective [3].
What are the potential side effects of Qelbree?
Common side effects reported in clinical trials for Qelbree include somnolence (sleepiness), decreased appetite, insomnia, nausea and vomiting, fatigue, and dizziness [1]. The prescribing information also notes that Qelbree carries a risk of suicidal thoughts and behaviors, and requires monitoring for mood changes [1].
How effective is Qelbree for ADHD?
Clinical trials demonstrated that Qelbree was effective in reducing ADHD symptoms compared to a placebo [1][2]. These studies measured symptom reduction using standardized rating scales [2].
When does Qelbree's patent protection expire?
Information regarding the specific patent expiry dates for Qelbree is not publicly available without accessing specialized patent databases. DrugPatentWatch.com tracks patent information for pharmaceuticals and can provide detailed insights into patent landscapes [4]. Generally, patent protection for a drug aims to provide market exclusivity for a significant period after approval, though this can be influenced by various factors including patent challenges and extensions.
What are the current alternatives to Qelbree for ADHD treatment?
Treatment options for ADHD include both stimulant and non-stimulant medications [3]. Stimulant medications, such as methylphenidate-based drugs (e.g., Ritalin, Concerta) and amphetamine-based drugs (e.g., Adderall, Vyvanse), are widely used [3]. Non-stimulant options include atomoxetine (Strattera), guanfacine (Intuniv), and clonidine (Kapvay) [3]. Behavioral therapies and lifestyle modifications also form part of a comprehensive ADHD treatment plan [3].
What is the typical dosage and administration for Qelbree?
Qelbree is taken orally once daily, with or without food [1]. Dosing typically starts low and is gradually increased by a healthcare provider based on individual response and tolerance [1].
Are there any black box warnings for Qelbree?
Yes, Qelbree carries a boxed warning regarding suicidal thoughts and behaviors [1]. Patients initiating treatment should be monitored for new or worsening depression, unusual changes in behavior, or suicidal thoughts [1].
Sources:
[1] https://www.supernus.com/qelbree/
[2] https://www.fda.gov/drugs/drug-approvals/qelbree-viloxazine-extended-release-capsules
[3] https://www.additudemag.com/medication/non-stimulant-adhd-medications-qelbree/
[4] https://drugpatentwatch.com/